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Tumour necrosis factor receptor-associated factor 6 (TRAF6) has been implicated in breast cancer 
and osteoclastic bone destruction. Here, we report that 6877002, a verified small-molecule inhibitor 
of TRAF6, reduced metastasis, osteolysis and osteoclastogenesis in models of osteotropic human 
and mouse breast cancer. First, we observed that TRAF6 is highly expressed in osteotropic breast 
cancer cells and its level of expression was higher in patients with bone metastasis. Pre-exposure 
of osteoclasts and osteoblasts to non-cytotoxic concentrations of 6877002 inhibited cytokine-
induced NFκB activation and osteoclastogenesis, and reduced the ability of osteotropic human 
MDA-MB-231 and mouse 4T1 breast cancer cells to support bone cell activity. 6877002 inhibited 
human MDA-MB-231-induced osteolysis in the mouse calvaria organ system, and reduced soft 
tissue and bone metastases in immuno-competent mice following intra-cardiac injection of mouse 
4T1-Luc2 cells. Of clinical relevance, combined administration of 6877002 with Docetaxel reduced 
metastasis and inhibited osteolytic bone damage in mice bearing 4T1-Luc2 cells. Thus, TRAF6 
inhibitors such as 6877002 – alone or in combination with conventional chemotherapy - show 
promise for the treatment of metastatic breast cancer. 
Keywords 




The TNF receptor associated factor (TRAF) protein family is a class of adaptor proteins that is 
implicated in inflammation and cancer [1, 2]. In the skeleton, members of the TRAF family 
serve as a point of convergence for multiple pathways for inflammatory mediators and bone-
derived factors [3-6]. A number of studies have uncovered the role of TRAF2, TRAF5, and 
TRAF6 in the regulation of bone growth and remodelling[7]. Of these three TRAF proteins, 
TRAF6 is unique and it has emerged as the major regulator of osteoclastogenesis. TRAF6s 
plays a critical, nonredundant role in nuclear factor of activated B cells (NFB) ligand 
(RANKL)-induced signalling and osteoclast formation, survival and activity [4, 8-10]. Mice 
deficient in TRAF6 are characterised by severe osteopetrosis and impaired tooth eruption due 
to complete absence of osteoclasts [9-12]. Additionally, TRAF6 activation is also essential for 
multiple bone derived and systemic mediators that plays a key role in osteoclastogenesis in 
health and disease. The list includes interleukin 1 (IL1), Cluster of differentiation 40 ligand 
(CD40L) and transforming growth factor -TGF [5-7]. Engagement of these ligands with 
their membrane receptors initiates the biding of TRAF6 to its conserved motif in the 
intracellular domain of the receptor and as a result it induces the activation of various receptor-
associated factors including TGF activated kinase 1 (TAK1), TGF activated kinase 1 binding 
protein 2 (TAB2) and the IB kinase (IKK) to the receptor/TRAF6 complex[1, 2, 4, 5, 13-16]. 
This in turn leads to the activation of a plethora of signalling proteins and transcription factors 
essential for osteoclast development, particularly NFB and members of the activator protein 
1 (AP-1) family such as cFos and nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1) 
[7, 11].  
Excessive osteoclastic bone resorption is the leading cause of bone pain and morbidity in 
advanced breast cancer patients  [17]. There is strong emerging evidence to implicate TRAF6 
in breast cancer metastasis. TRAF6 is over-expressed in triple-negative human breast 
 5 
carcinoma cells and its expression predicts metastatic outcome [18-23]. In addition, TRAF6 
activity promotes the motility and metastasis of various breast cancer cell lines[18, 24-27]. 
Although, little is known regarding the role of TRAF6 in the development of bone metastasis 
in breast cancer patients, bone- and breast cancer-derived factors that are known to activate 
TRAF6, including RANKL and IL1, are implicated in all aspects of osteolytic breast cancer 
metastasis including the homing, colonisation and osteolytic activity of breast cancer cells in 
the skeleton (osteotropic cells) [28-37].  
In 2015, Nicolaes and colleagues described the discovery of a novel class of small-molecule 
inhibitors of TRAF6 and demonstrated the functional specificity of the agent 6877002 for 
TRAF6/CD40 binding[38]. In view of the fact that CD40, RANK and the IL1R adaptor protein 
(IRAK) share a distinctive TRAF6-binding motif [39-41], we carried out an in vitro, ex vivo and in 
vivo investigation that provides pharmacological evidence to suggest that inhibition of 
TRAF6/NFB signalling by 6877002 reduced cytokine- and breast cancer induced bone cell 
activity, metastasis and osteolysis in osteotropic models of the triple-negative breast cancer cells 
human MDA-MB-231 (MDA-MB-231-BT) and mouse 4T1-Luc2. Of clinical relevance, combined 
administration of 6877002 and Docetaxel reduced soft tissue and skeletal breast cancer metastasis 
– thus indicating that targeting of TRAF6/NFB signalling - in combination with conventional 
chemotherapy - shows promise for the treatment of advanced breast cancer. 
2. Material and Methods 
2.1 Reagents 
The TRAF/NFB inhibitor 6877002 was a kind gift from Professors Gerry Nicolaes 
(Maastricht University) and Esther Lutgens (University of Amsterdam, The Netherlands), and 
purchased from Tocris Biosciences (Bristol, UK). Tissue culture medium (DMEM and alpha-
MEM) was obtained from ThermoFisher (Leicestershire, UK). Anti-TRAF6 (D21G3), anti-
CD40 (E2Z7J),  anti-IKK (D30C6), anti-IKK (3G12), anti-phospho IKK/ Ser176/180 
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(16A6), anti-phospho IB Ser36 (14D4), anti-IB (L35A5), were purchased from Cell 
Signalling Technology (MA, USA) and used at a dilution of 1:1000. Rabbit anti-actin (clone 
AC-15; 1:1000) was purchased from Sigma-Aldrich (Dorset, UK).  For immunoprecipitation 
studies, the anti-RANK antibody (B-8; 2 µg per 100-500 µg of total protein) was purchased 
from Santa Cruz (Dallas, USA). Mouse macrophage colony stimulating factor (M-CSF) was 
obtained from R&D Systems (Abingdon, UK) and receptor activator of NFB ligand 
(RANKL) was a gift from Patrick Mollat (Galapagos SASU, France). 
2.2 Cell lines and conditioned medium 
The human breast cancer cell line MDA-MB-231 and the mouse preosteoblast cell line 
MC3T3-E1 clone 4 were originally purchased from ATCC. The osteotropic derivatives of 
MDA-MB-231,  MDA-MB-231-BT [42] and MDA-MB-231-IV [43] were generated by 
independent groups through repeated in vivo passages and validated for their ability to colonize 
bone and to cause osteolysis. Parental 4T1 and the osteotropic 4T1-BT were a generous 
donation from Peter M. Siegel. Mouse 4T1 Luciferase expressing cells (4T1-Luc2) cells were 
a kind gift from Dr. Munitta Muthana (Sheffield, UK). The pre-osteoclast-like cell line RAW 
264.7 were originally purchased from ATCC (Manassas, VA) and were a kind gift from 
Professor Dominique Heymann (INSERM, University of Nantes, France).  Breast cancer cells 
were cultured in a D-MEM, whereas RAW 264.7 pre-osteoclasts and MC3T3-E1 
preosteoblasts were cultured in alpha-MEM. All media was supplemented with 10% fetal calf 
serum (FCS), glutamine (2mM), penicillin (100U/ml), and streptomycin (100µg/ml).. For 
studies involving breast cancer conditioned medium, breast cancer cells were allowed to grow 
to 80% confluence in standard medium and then the tissue culture medium was refreshed with 
serum free D-MEM. After 16 hours, the conditioned medium was removed, filtered (0.22 μm 
filter diameter) and added to cultures (10 - 20% v/v) for the desired period [44].  
2.3 Osteoblast viability, differentiation and bone nodule formation 
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Primary osteoblasts were isolated from the calvarial bones of 2-day-old mice by sequential 
collagenase digestion and were maintained in standard alpha-MEM for 48 hours [44]. For 
assessing osteoblast differentiation, calvarial osteoblasts or MC3T3 were plated (7x103 cells/ 
well) for 24 hours and in the following day vehicle, test compound and/or breast cancer cell 
conditioned medium (20% v/v) were added.  For bone nodule assays, calvarial osteoblasts and 
MC3T3 were cultured into 12-well (200 x 103 cells/well) in standard medium supplemented 
with L-ascorbic acid (50 µg/ml) and β-glycerophosphate (10M) in the presence and absence 
of vehicle, test compound and/or breast cancer conditioned medium (20% v/v). Osteoblast 
viability, differentiation and bone nodule formation were determined by the AlamarBlue assay, 
alkaline phosphatase (Alk Phos) assay and alizarin red (ALZ) staining, respectively [44]. 
2.4 Osteoclast formation, apoptosis and bone resorption 
Osteoclast formation and survival were studied in cultures of human peripheral blood 
monocytes, mouse bone marrow (BM) cells and RAW 264.7 preosteoclast cells seeded in the 
presence and absence of mouse calvarial osteoblasts. Human CD14+ monocytes were isolated 
from peripheral blood mononuclear cells of healthy volunteers by  Ficoll-Pacque separation 
followed by CD14-positive selection beads (Miltenyi Biotec, UK) as described in [44]. In 
mouse osteoclast cultures, BM cells were flushed from the long bones of 3-5 week old mice 
and cultured in standard alpha-MEM with M-CSF (100ng/ml) for 48 hours to enrich for M-
CSF generated macrophages. Isolated cells were cultured in 96-well plates (human CD14+: 45 
x 103 cells/well, Mouse BM cells: 12 x 103 cells/well) in standard alpha-MEM supplemented 
with RANKL (100 ng/ml) and M-CSF (25ng/ml) for up to 5 days in the presence and absence 
of vehicle, test compound and/or breast cancer cells or their conditioned medium (20% v/v). 
RAW 264.7 were cultured in 96-well plates (1000 cells/well) supplemented with RANKL (100 
ng/ml) with or without the aforementioned conditions. For cultures involving breast cancer 
cells or their derived factors, human MDA-MB-231 or 4T1-Luc2 breast cancer cells (300 
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cells/well) were added to each 96-well [44] In mouse osteoblasts - bone-marrow cell co-
cultures, calvarial osteoblasts were isolated as described above and plated into 96-well plates 
(8 x 103 cells/well) for 24 hours. BM cells (2x105 cells/well) were added and the co-culture 
was maintained in alpha-MEM, supplemented with 10% FCS and 1,25-(OH)2-vitamin D3 
(10nM) for up to 5 - 7 days with replacement of the culture medium every 48 hours. Three days 
before the termination of the culture, vehicle, test compound and/or breast cancer cells or their 
conditioned medium (20% v/v) were added in the presence or absence of IL1 (100 ng/ml) 
[44]. Multinucleated osteoclasts with 3 or more nuclei were identified using Tartrate-resistant 
Acid Phosphatase (TRAcP) staining[44]. For morphometrical assessment of apoptosis, cultures 
were fixed, stained with 1µg/ml 4,6-diamidino-2-phenylindole (DAPI) and scored on the basis 
of nuclear morphology (6 microscopic fields per treatment group) by fluorescence 
microscopy[45]. Inactive (p-30) and cleaved (p-19) caspase-3 expression was assessed by 
Western blotting as described in [45]. Activated caspase-3 and inactive caspase-3 were detected 
using Western blotting as described below. For studies involving assessment of osteoclast 
activity, mature osteoclasts were plated on Corning® Osteo Assay Surface multiple well plates 
(Corning, USA), resorption pits were visualised using an Olympus ScanR microscope and 
resorbed area was quantified by ImageJ.   
2.5 Breast cancer cell motility 
The migration of breast cancer cells was assessed using time-lapse microscopy and T-scratch 
analysis program[46]. Breast cancer cell invasion was assayed using the transwell migration 
assay (Transwell inserts, 8 µm, Corning, UK) and inserts containing invasive cells were stained 
with haemotoxylin and eosin and the number of invasive cells were quantified using 
ImageJ[46]. RANKL (100ng/ml) was used as the chemoattractant.  
2.6 Western Blotting 
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Western blot was used to assess expression and phosphorylation of protein in human and 
murine bone and breast cancer cells. Briefly, osteoclasts, osteoblasts and breast cancer cells 
were cultured in standard media in 12-well plates until confluency. Cultures were incubated in 
serum free tissue culture medium for 1 hour for primary cells and 16 hours for cell lines. 
Vehicle or 6877002 were then added for the desired period of time. Cells were lysed, total 
protein (50-100µg) was resolved by SDS-PAGE on 12% polyacrylamide SDS gels and 
transferred onto PVDF membranes (BioRAD, UK)[47]. For immunoprecipitation studies, and 
SureBeads™ Protein A Magnetic Beads were used as per manufacturer’s instructions.  
Immunoblots were probed with appropriate antibodies using a horseradish peroxidase-
conjugated secondary antibody (Jackson labs, UK) and visualised using chemiluminescence 
(Amersham, UK) on a Biorad ChemiDocMP imaging system[47]. 
2.7 Measurement of tumour-derived factors 
Tumour-derived factors in conditioned medium from osteotropic human MDA-MB-231-BT 
breast cancer cells were determined by Proteome Profiler Human XL Cytokine Array Kit 
(ARY022, R&D Systems, Abingdon, UK), according to the manufacturer’s instructions. 
2.8 Quantitative PCR 
The expression of RANKL and OPG were detected using quantitative PCR (qPCR). Briefly, 
samples were lysed using TRIzol reagent, quantified using a nanodrop (Thermo Scientific) and 
complementary DNA (cDNA) was generated using Invitrogen SuperScript III Reverse 
Transcriptase kit, according to manufacturer’s instructions. The following primers were 
designed using the Ensembl genome browser and Roche website for the amplification of mouse 
OPG (forward primer: 5’- atgaacaagtggctgtgctg-3’, reverse primer 5’-cagtttctgggtcataatgcaa-
3’); mouse RANKL (forward primer: 5’-tgaagacacactacctgactcctg-3’, reverse primer 5’-
ccacaatgtgttgcagttcc -3’); mouse GAPDH (forward primer: 5’- cctgaattttaagctacacacagc -3’, 
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reverse primer 5’- ctggcactgcacaagaagat -3’). Levels of gene expression were expressed as 
copy number per micro-gram of total RNA and GAPDH was used for cDNA normalization.  
2.9 Transcription factors assays 
Nuclear extracts from osteoclasts, osteoblasts and breast cancer cells were prepared using a 
nuclear extraction kit (Active Motif, Rixensart, Belgium) and DNA binding was measured 
using TRANSAM ELISA kit for p65 NFB, cFOS and NFATc1 (Active Motif, Rixensart, 
Belgium), according to the manufacturer’s instructions.   
2.10 Mouse calvaria – breast cancer cell co-culture system 
The effects of 6877002 on human breast cancer cells induced osteolysis were studied ex vivo 
using an adaptation of the mouse calvarial organ culture as described in[48]. Briefly, breast 
cancer cells (1 × 102 cells/well) were plated in 48-well plates containing standard medium. 
Mouse calvarias were isolated from 2-day-old mice, divided into equal halves along the 
medium sagittal suture and each half was placed into culture on stainless steel rafts in 48-well 
plates containing breast cancer cells. Tissue culture medium containing test agents was changed 
every 48 hours and the cultures were terminated after 7 days. Bone volume was assessed by 
using microCT at a resolution of 5m. 
2.11 Intracardiac injection of murine 4T1-Luc2 breast cancer cells  
The effects of 6877002 on metastasis were studied in mice following intracardiac injection of 
the syngeneic breast cancer cells 4T1-Luc2 cells. Experimental protocols for these studies were 
approved by the Ethics Committee at the University of Sheffield and were conducted in 
accordance with the UK Home Office regulations. Briefly, 8 week‐old female BALB/c mice 
were anesthetized and injected into the left cardiac ventricle with a single-cell suspension of 
4T1-Luc2 (1 × 105 cells /100 µL). Mice were randomly allocated into 4 groups groups (8 mice 
per group) and received daily intraperitoneal (IP) injection of vehicle (5% DMSO in PBS), 
6877002 (20mg/kg/daily) and/or Docetaxel (15mg/kg/week). Mice were monitored for 
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cachexia (evaluated by body weight) and behaviour. No overt signs of toxicity were observed 
as deemed by behavior and changes in body weight compared to vehicle controls. In addition, 
previous studies have demonstrated no negative effects on hematopoiesis with up to 6 weeks 
of daily treatment [49]. Metastases were monitored thrice-weekly using the IVIS system and 
mice were sacrificed by cervical dislocation after 11 days.  
2.12 Micro-computed tomography 
Bone volume was measured in mouse calvaria and left proximal tibia (400 slices distal of the 
growth plate) using microCT analysis (Skyscan 1172 instrument, Bruker, Belgium) set at a 
resolution of 4m and 60kV and 150A. Images were reconstructed and analysed using 
Skyscan NRecon and CTAn (Bruker, Belgium), according to manufacturers’ instructions and 
as described in [50]. 
2.13 Statistical Analysis 
Results were reported as mean ± standard deviation (SD) unless otherwise stated. A p-value 
value of 0.05 or below was considered statistically significant. All statistical analyses carried 
out between two groups were student T-test and between three groups analysis of variance 
(ANOVA) was used. All tests were conducted in GraphPad Prism 8.0 for Mac (La Jolla 
California, USA). Retrospective analysis of TRAF1 to TRAF6 expression with respect to bone, 
brain, liver and lung metastases was examined in the GSE14020 dataset. P-values were derived 
from Wilcoxon test and were two-tailed.  
3. Results 
3.1 6877002 prevents CD40L- and RANKL-induced signalling and osteoclast formation      
Previous studies have shown that 6877002 inhibited CD40 and TRAF6 interactions[38, 51, 
52]. In view of this and the fact that CD40 and RANK share a distinctive TRAF6-binding motif 
[39-41], we tested the effects of 6877002 on RANKL-induced osteoclastogenesis in the 
presence and absence of CD40L. Our present data demonstrate that exposure of human pre-
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osteoclasts to CD40L stimulated the phosphorylation of IKK, IKK and IB (Fig. 1a and 
Fig.S1a) and these effects were significantly reduced by treatment with 6877002 at 3M and 
completely abolished in cultures exposed to 10M of 6877002. Furthermore, CD40L 
significantly enhanced RANKL-induced osteoclast formation (Fig. 1b-c) and survival (Fig. 
1d). Importantly, pre-treatment of these cultures with 6877002 (3M) prior the addition of 
CD40L (100 – 200ng/ml) completely abolished these effects in cultures stimulated with 25 
ng/ml RANKL and significantly reduced the number of mature osteoclasts in cultures 
stimulated with 50 ng/ml RANKL (p < 0.01). Representative photomicrographs of osteoclasts 
from the experiment described are shown in Fig. 1c. Next, we went on to test the effects of 
6877002 on RANKL induced signalling and osteoclast formation, apoptosis and activity. As 
shown in Fig. 1e-g and supplementary Fig.S1b, pre-treatment of M-CSF generated osteoclast 
precursors with 6877002 (3M) inhibited RANKL-induced RANK/TRAF6 binding (Fig.S1b), 
IB phosphorylation (Fig. 1e and Fig.S1b) and DNA binding of NFB, cFOS and NFATc1 
(Fig. 1f). Consistently, 6877002 (3M) inhibited RANKL-induced osteoclast formation in a 
concentration dependent manner (Fig. 1g), without affecting the proliferation of osteoclast 
precursors at concentration up to 10M (Fig. 1h-i). This excludes the possibility that the 
inhibitory effect on osteoclast formation and NFB activation was mediated by a cytotoxic 
effect.  
RANKL plays a key role in the survival of mature osteoclasts, the determinant of bone 
resorption and osteolysis [53]. With this in mind, we next examined the effects of 6877002 on 
the survival, apoptosis and bone resorption in cultures of mature osteoclasts. First, we 
generated RANKL and M-CSF dependent mature osteoclasts and then exposed these cells to 
different concentrations of 6877002 and RANKL (Fig. 1, j – m). Exposure of mature 
osteoclasts to 6877002 at 3M significantly inhibited the survival of mature osteoclasts (Fig. 
1j), induced caspase-3/7 activation after 6 hours (Fig. 1k) and caused osteoclast apoptosis after 
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24 hours (Fig. 1l), as evident by nuclear condensation and DNA fragmentation as assessed by 
DAPI and TUNEL assays, respectively. We subsequently established that exposure of 
surviving mature osteoclasts to 6877002 at 1M failed to affect osteoclast activity, as 
evidenced by the lack of effect on resorption area (Fig. 1m). Altogether, these results 
demonstrate that exposure of mature osteoclasts and their precursors to 6877002 inhibits 
CD40L- and/or RANKL-induced signaling and osteoclastogenesis. 
3.2 6877002 reduces osteoblast support for osteoclastogenesis 
Osteoblasts regulate osteoclastogenesis through secretion of various factors including 
RANKL[54, 55] and CD40L[56, 57]. Thus, we next utilized the in vitro mouse calvarial 
osteoblast –BM cell co-culture system to test the effects of 6877002 on osteoblast support for 
osteoclastogenesis. As shown in Fig. 2a, pretreatment of osteoblasts with 6877002 (3M) prior 
to the addition of BM cells significantly inhibited osteoclast formation in control cultures and 
in co-cultures treated with the pro-inflammatory cytokine IL1 (100ng/ml) (Fig. 2a). 
Mechanistic studies in calvarial osteoblasts showed that exposure to 6877002 (0 - 10M) for 1 
hour prior to the addition of IL1 (100ng/ml) significantly inhibited IB phosphorylation 
within 15 minutes (Fig.2b and Fig.S1c) and reduced RANKL/OPG ratio after 24 hours (Fig. 
2c). Interestingly, exposure of calvarial osteoblasts to 6877002 (3M) had no effects on 
osteoblast viability (Fig. 2d) or alkaline phosphatase (ALP) activity (Fig. 2e) in the presence 
or absence of CD40L (100ng/ml) which has been demonstrated to induce proliferation of 
stromal/preosteoblast cells under pathological conditions of bone loss [58]. 6877002 (3M) 
also failed to affect the ability of the mouse MC3T3 pre-osteoblasts to form bone nodule in 
vitro (Fig. 2f). 
3.3 TRAF6 expression is associated breast cancer bone metastasis  
A retrospective analysis of a cohort of patients with metastatic breast cancer [59, 60] revealed 
that expression of TRAF6 – but not TRAF1 to 5 - is strongly associated with bone metastasis 
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when compared to brain, liver and lung metastasis (Fig.3a, p = 0.003, n = 65). Similarly, high 
expression of RANKL was also found to be associated with bone metastasis in breast cancer 
patients when compared to brain, liver and lung metastasis (Fig. S2). To further evaluate the 
potential role of TRAF6 in the regulation of osteolytic activity of breast cancer cells, we 
assessed the expression of TRAF6 in osteotropic breast cancers and their parental controls. 
These experiments confirmed that TRAF6 expression is significantly upregulated in the 
osteotropic human breast cancer cell lines MDA-MB-231-BT and MDA-MB-231-IV, when 
compared to their parental clone MDA-MB-231 (Fig. 3b and S3a). Similarly, high level of 
TRAF6 expression was detected in an osteotropic clone of mouse triple-negative breast cancer 
cell line 4T1-BT, when compared to its parental 4T1-P control (Fig. 3d and S3b).  
3.4 6877002 reduces osteolytic behaviour of human and mouse breast cancer cells 
Guided by these findings and in view of evidence demonstrating that breast cancer cells in the 
skeleton have differential transcriptional profiles leading to osteotropic phenotype [55, 61-63], 
we went on to tested the effects of the verified inhibitor of TRAF6 6877002 [38] on the ability 
of the osteotropic human MDA-MB-231-BT and mouse 4T1-Luc2 cells to grow, move and 
influence osteoclast and osteoblast differentiation, survival and activity in vitro. First, we 
showed that 6877002 reduced the growth of osteotropic human MDA-MB-231-BT and mouse 
4T1-Luc2 cells in a concentration-dependent manner (Fig. 4a-b). The concentration of 6877002 
that half maximally inhibited cell viability (IC50) were 31.5 ± 1.02M and 24.3 ± 1.03M in 
human MDA-MB-231-BT and mouse 4T1-Luc2 cells, respectively. Next, we tested the effects 
of 6877002 on the ability of human MDA-MB-231-BT and mouse 4T1-Luc2 cells to influence 
osteoclast formation and osteoblast differentiation at concentrations that failed to inhibit cell 
growth in vitro. As shown in Fig. 4 (panels c -d), 6877002 (0.1 – 3M) reduced the formation 
of osteoclasts in RAW 264.7 pre-osteoclast-like cells treated with RANKL (25ng/ml) in the 
presence of human MDA-MB-231-BT, mouse 4T1-Luc2 or their derived factors (20% v/v). In 
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contrast, 6877002 (0.1 – 3M) had no effects on the proliferation (Fig. 4e) or differentiation 
(Fig. 4f) of mouse MC3T3 pre-osteoblasts cultured in the presence of human MDA-MB-231-
BT, mouse 4T1-Luc2 or their derived factors (20% v/v). Collectively, these results show that 
6877002 inhibits cytokine-, osteoblast- and breast cancer-induced osteoclastogenesis without 
affecting osteoblast growth and differentiation. 
3.5 6877002 protects against human breast cancer induced osteolysis  
Next, we took advantage of the ex vivo calvarial organ culture system to test the effects of 
6877002 on the ability of the human MDA-MB-231-BT breast cancer cells to cause osteolysis 
in an immuno-competent setting. Graphic representation of the human MDA-MB-231-BT cells 
- mouse calvarial organ co-culture system used is shown in Fig. 5a. First, we demonstrated that 
addition of 6877002 (10M) enhanced bone volume in mouse calvarial organ after 7 days (Fig. 
5b, left). Next, we showed that exposure of mouse calvarial organ to IL1 (100ng/ml) or human 
MDA-MB-231-BT cells caused a significant osteolytic bone damage and pre-treatment of the 
calvarial tissue with 6877002 (10M) significantly inhibited these effects (Fig. 5b). To 
examine the mechanism(s) by which 6877002 exerts this osteoprotective action in this model, 
we employed an analytic approach that utilizes data from protein expression arrays. Next, we 
carried out analysis of the levels of cytokines and chemokines in conditioned medium from the 
mouse calvarial – human MDA-MB-231-BT organ co-culture (Fig. 5a and b) together with 
examination of the transcriptional responsiveness of p65 in human MDA-MB-231. Exposure 
to 6877002 (10M) reduced the levels of stromal-derived factor-1 (SDF-1), brain-derived 
neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), granulocyte-
macrophage colony-stimulating factor (GM-CSF), monocyte chemoattractant Protein-1 (MCP-
1) and IL-6, -8 and -17 (Fig. 5c) - factors that are known to regulate breast cancer – bone cell 
interactions [46, 64-75]. In view of this, we also carried out quantitative analysis of NFB 
expression in MDA-MB-231-BT from the experiment described in Fig. 5a and b and mouse 
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osteoclasts that revealed that exposure to 6877002 (3M) exerted a non-significant trend 
towards reduced NFB DNA binding (p > 0.05) in human MDA-MB-231-BT (Fig. 5d, left). 
A similar trend was also observed in cultures of mouse osteoclasts (Fig. 5d, right) exposed to 
conditioned medium from the human MDA-MB-231-BT - mouse calvarial organ culture. Next, 
we went on to show that 6877002 (10M) reduced the ability of the osteotropic human MDA-
MB-231-BT breast cancer cells to migrate (Fig. 5e-f) and invade (Fig. 5g-h) in the presence 
and absence of RANKL (100ng/ml). Together, these results suggest that 6877002 reduces the 
osteotropic behaviour of the human breast cancer cells in the models described. 
3.6 6877002 reduces breast cancer metastasis  
Previous studies have shown that NFκB activation is implicated in breast cancer bone 
metastasis and resistance to chemotherapy[14, 18, 76-81]. Thus, we sought to determine 
whether 6877002, alone or in combination with a chemotherapeutic agent - affects breast 
cancer bone metastasis. To investigate this, we used the 4T1-Luc2 model. The advantage of 
this model is that the mouse 4T1-Luc2 cells are both syngeneic and osteotropic when 
inoculated in immunocompetent mice. First, we observed that exposure of 4T1-Luc2 to 
6877002 (10M) significantly enhanced the in vitro anti-tumour effects of Docetaxel by up to 
36.5± 3.9%. Additionally, combination index values were calculated using the Chou-Talalay 
method revealing that 6877002 (10M) plus docetaxel (0.3-1M) were synergistic as shown 
by CI values <1. (Fig. 6a-b). Next, we tested if administration of 6877002 sensitizes the 
osteotropic and syngeneic 4T1-Luc2 breast cancer cells to Docetaxel in immuno-competent 
mice (Fig. 6c). As shown in Figure 6, panels d-h, administration of 6877002 (20mg/kg/day) 
alone and in combination with Docetaxel (15mg/kg/week) reduced both soft tissue (Fig. 6d-e) 
and bone (Fig. 6f) metastases in mice inoculated with the 4T1-Luc2 cells. Detailed micro-
computed tomography (microCT) analysis of bone volume at the tibial metaphysis of these 
mice showed that only combined administration of 6877002 (20mg/kg/day) and Docetaxel 
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(15mg/kg/week) exerted a significant reduction in bone loss as evidenced by an increased bone 
volume (BV/TV; Fig. 6g). Representative photomicrographs of microCT scan of mouse tibia 
showing the osteoprotective effects of combined administration of 6877002 (20mg/kg/day) and 
Docetaxel (15mg/kg/week) are shown in Fig. 6, panel h.  
4. Discussion   
Advanced breast cancer patients develop osteolytic metastasis characterized by skeletal tumour 
burden and excessive osteoclastic bone destruction [17]. The TRAF6/NFB axis has been 
implicated in triple-negative breast cancer and plays a critical role in the regulation of 
osteoclast formation, survival and activity [9-12, 18-23]. Nonetheless, the role of TRAF6 on 
the osteotropic behaviour of breast cancer cells in bone is poorly understood, and no agent that 
directly disrupts the binding of TRAF6 to RANK has been tested on models of breast cancer 
osteolytic metastasis. We have observed that osteotropic breast cancer cells express highly 
levels of TRAF6 and its expression in breast cancer patients is associated with bone metastasis 
in breast cancer patients. Thus, we utilized the verified small molecule inhibitor of 
TRAF6/CD40 binding 6877002 [38] to provide evidence to whether NFB inhibition at the 
level of TRAF6 is of value in the reduction of skeletal and non-skeletal complications 
associated with breast cancer osteolytic metastasis. 
Using various mechanistic studies in human and mouse breast cancer and bone cells, we 
demonstrated that 6877002 inhibited CD40L-induced NFB activation in bone marrow derived 
macrophage (pre-osteoclasts) and osteoblasts. This finding is in agreement with previous 
observations by Nicolaes and colleagues[38], and has inspired us to carry out an extensive in 
vivo, ex vivo and in vitro investigation on the effects of this agent on the ability of osteotropic 
breast cancer cells to grow, move and influence bone cell viability, differentiation and activity. 
In view of the fact that receptors for RANKL and IL1 share a distinctive TRAF6-binding 
motif with CD40 [6, 39-41], we carried additional mechanistic experiments that showed that 
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6877002 reduced RANKL-induced binding of TRAF6 to RANK, and inhibited RANKL-, 
CD40L- and IL1-induced NFB activation in osteoclasts and their precursors (Fig S4). In 
addition to NFB, TRAF6 in osteoclasts is known to activate multiple signaling pathways, 
particularly NFATc1 and c-Fos [11, 82]. We confirmed that 6877002 completely abolished 
RANKL-induced DNA binding of p65NFB as well as NFATc1 and c-Fos in osteoclasts and 
their precursors. Interestingly, 6877002 failed to inhibit NFB activation in osteoclasts exposed 
to both RANKL and conditioned medium from breast cancer cells. While we cannot readily 
explain this, our previous [83] and present analysis of the tumour-derived factors in conditioned 
medium from osteotropic human MDA-MB-231 detected a plethora of pro-inflammatory 
mediators that are known to directly and indirectly regulate NFB expression, independent of 
TRAF6 activation. Notwithstanding this, we cannot exclude the disruption of the activity other 
TRAF proteins, in particular TRAF1, 2 and 3 that have already been shown to be affected by 
6877002 in other models[38]. 
The RANKL/RANK/TRAF6 pathway plays a critical role in the regulation of 
osteoclastogenesis in health and cancer [28-33], and pro-inflammatory factors including 
CD40L and IL1 enhance the osteolytic activity of RANKL in bone cells [6, 56, 57]. In the 
present study, 6877002 completely abolished RANKL- induced osteoclast formation in the 
absence and presence of CD40L and significantly reduced the ability of osteoblasts to support 
osteoclast formation in the presence of IL1. Further functional and mechanistic data revealed 
that the anti-osteoclastic effects of 6877002 were observed at concentrations that inhibited IB 
phosphorylation in osteoclasts, osteoblasts and their precursors, reduced RANKL production 
by osteoblasts and induced apoptosis in mature osteoclasts. of note, 6877002 had no effect on 
the survival pre-osteoclasts nor affected the ability of mature osteoclasts to resorb bone at 
concentrations that completely abolished cytokine-induced osteoclast formation and NFB 
signaling. These findings are consistent with our working hypothesis that TRAF6/NFκB 
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inhibition by this compound suppresses TRAF6-depedent RANKL signaling and osteoclast 
formation directly and indirectly by suppressing the ability of osteoblasts and pro-
inflammatory that activate TRAF6, namely CD40L and IL1 to induce osteoclastogenesis. It 
is also important to reiterate that other TRAF proteins such as TRAF1, 2, and 3 which are 
known to be affected by 67877002 are also implicated in the regulation of RANKL-induced 
osteoclast formation[38, 84-87].  
Breast cancer cells acquire osteotropic characteristic compared to their parental counterpart 
[55, 63] and our previous studies have shown that NFB inhibition at the IKK level reduces 
the ability of osteotropic breast cancer cells to metastasise to bone and influence bone cell 
activity[46, 88, 89]. Our present in vivo, ex vivo and in vitro studies using the osteotropic clones 
of human MDA-MB-231 and mouse 4T1-Luc2 complement our previous findings and show 
that 6877002 significantly reduced the ability of these cells to migrate, invade and support 
osteoclastogenesis in the presence of RANKL. These in vitro anti-migratory and anti-
osteoclastic effects were observed at concentrations that inhibited NFB activation. Using 
immuno-competent mice and their calvarial bone, we showed that 6877002 suppressed the 
ability of the syngeneic 4T1 breast cancer cells to metastasise to the skeleton in mice and 
reduced osteolytic bone damage caused by 4T1-Luc in these mice and by human MDA-MB-
231 in mouse calvarial bone organ culture. Additionally, combined administration of 6877002 
and Docetaxel exerted a synergistic anti-metastatic and anti-osteolytic effects when compared 
to vehicle or either treatment as a single-agent. Although these results imply that 6877002 may 
be of value in the treatment of breast cancer bone metastasis, our present studies were restricted 
to the osteotropic human MDA-MB-231 and mouse 4T1-Luc2 models described. Furthermore, 
neither 6877002 nor Docetaxel - as single agents – reduced osteolytic bone damage in the 4T1-
Luc2 mouse model. In fact, only mice that received combined treatment exhibited significant 
protection against bone damage, evident by an increase in bone volume. This had led to the 
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hypothesis that administration of 6877002 in mice – but not in our present in vitro and ex vivo 
models - was insufficient to inhibit NFB activation to a level that suppresses breast cancer-
induced osteoclastogenesis. Some evidence for this hypothesis comes from data from in vitro 
studies that showed that 6877002 was incapable of inhibiting NFB activation induced by bone 
and tumour-derived factors. However, histological examination of mouse long bones revealed 
that mice bearing 4T1-Luc2 cells from the vehicle treated group had suffered significant loss 
in bone and as a result no multi-nucleated osteoclasts were present. Thus, future studies are 
needed to study the effects of TRAF6 inhibitors such as the 6877002 on bone- and cancer cell 
– specific NFB activation and bone cell activity in a slower growing model, that faithfully 
recapitulates the progression of breast cancer bone metastasis in humans. 
In summary, the results presented in this study extend our previous findings on the role the 
NFB in cancer associated bone disease, but most importantly offer a new insight into the role 
of the TRAF6/NFB in the interaction between osteoclasts, osteoblasts and triple-negative 
breast cancer cells. Of clinical significance, our mouse studies provide pharmacological 
evidence to support the notion that NFB inhibition at the level of TRAF6 – in combination 
with the FDA-approved chemotherapeutic agent Docetaxel - may be of value in the reduction 
of soft tissue and bone metastasis associated with breast cancer. On the other hand, we have 
shown that TRAF6 inhibitors such as the 6877002 may not offer significant osteo-protection 
against breast cancer-induced bone damage as a single agent in the immuno-component mouse 
model described. Thus, combinational studies with anti-resorptive agents such as 
bisphosphonates in preclinical models of metastatic breast cancer are needed.  
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Figure 1. 6877002 inhibits CD40L- and RANKL-induced NFB activation and 
osteoclastogenesis. (a) Western blot quantification of phosphorylated and total IB in 
human pre-osteoclasts after exposure to CD40L (100ng/ml) in the presence and absence 
of 6877002 (0-10μM). (b) In vitro CD40L (100 – 200ng/ml) induced osteoclast 
formation in RANKL (100ng/ml) stimulated human pre-osteoclasts treated with vehicle 
or 6877002 (3μM) for 72 hours, as assessed by TRAcP assay. (c) Representative 
photomicrographs of TRAcP positive mature human osteoclasts from the experiment 
described in panel b (scale bar = 50 m). (d) In vitro osteoclast survival in CD40L and 
RANKL (100ng/ml) generated mature human pre-osteoclasts treated with vehicle or 
6877002 (3μM) for 48 hours, as assessed by TRAcP assay. (e) Western blot 
quantification of phosphorylated IB in human pre-osteoclasts pretreated with vehicle or 
6877002 (0-10μM) and exposed to RANKL (100ng/ml) for 5 minutes. (f) DNA binding 
of NFκB (left), cFOS (middle) and NFATc1 (right) in the cultures of human pre-
osteoclasts described in panel a. (g) In vitro RANKL (100ng/ml) induced osteoclast 
formation in human pre-osteoclasts treated with vehicle or 6877002 (3μM) for 72 hours. 
Osteoclast formation was as assessed by TRAcP assay and representative 
photomicrographs of TRAcP positive mature human osteoclasts from the experiment 
described are shown in the right (scale bar = 100 m). (h) In vitro survival in human pre-
osteoclasts treated with vehicle or 6877002 (3μM) for 72 hours. Cell viability was 
assessed by AlamarBlue assay and representative photomicrographs of pre-osteoclasts 
from the experiment described are shown in the right (scale bar = 100 m). (j) In vitro 
RANKL (100ng/ml) induced mature human osteoclast survival in the presence and 
Figure Legends Click here to access/download;Figure Legends;Bishop et al -
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absence of vehicle or 6877002 (0-3μM) for 48 hours. (k) Caspase-3/7 activation and 
(l)DNA fragmentation in mature osteoclasts from the experiment described in panel j 
after 16 and 48 hours, respectively. (m) In vitro RANKL (100ng/ml) induced bone 
resorption mature human pre-osteoclasts treated with vehicle or 6877002 (1μM) for 48 
hours. Values are mean ± SD; * p<0.05 and ** p<0.01 from vehicle; + p < 0.05 from 
vehicle plus RANKL; $ p < 0.05 from vehicle plus CD40L. 
Figure 2. 6877002 inhibits osteoblasts support for osteoclastogenesis in vitro. (a) In 
vitro osteoclast formation in mouse calvarial osteoblast - bone marrow cell co-cultures 
after exposure to IL1 (100ng/ml) in the presence and absence of 6877002 (0-10μM) for 
72 hours. (b) Western blot quantification of phosphorylated IB in human pre-osteoclasts 
pretreated with vehicle or 6877002 (0-10μM) and exposed to IL1 (100ng/ml) for 15 
minutes. (c) mRNA expression of RANKL and OPG after 24 hours in mouse osteoblasts 
from the experiment described in panel a. (d) In vitro viability of mouse calvarial 
osteoblast treated with vehicle or 6877002 (3μM) in the presence and absence of CD40L 
(100ng/ml) for 48 hours as assessed by AlamarBlue assay. (e) In vitro differentiation of 
mouse calvarial osteoblast treated with vehicle or 6877002 (3μM) in the presence and 
absence of CD40L (100ng/ml) for 48 hours as assessed by Alkaline phosphatase (ALP) 
assay. (f) In vitro bone nodule formation in cultures of mouse calvarial osteoblast treated 
with vehicle or 6877002 (3μM) in the presence and absence of CD40L (100ng/ml) for 48 
hours as assessed by alizarin red assays. Values are mean ± SD; * p<0.05 and ** p<0.01 
from vehicle; $ p < 0.05 from vehicle plus IL1. 
Figure 3. Increased expression of TRAF6 is associated with breast cancer bone 
metastasis in patients and breast cancer cells. (a) Retrospective analysis of patients 
 3 
samples (n = 65) showing increased expression of TRAF6, but not TRAF 1 - 5, is 
associated with breast cancer bone metastasis. (b-c) Western blot quantification of 
TRAF6 in human MCF10a, MCF7, ZR-75-1, SK-BR-3, MDA-MB-468, MDA-MB-231, 
MDA-MB-231-BT and MDA-MB-231-IV (b) and mouse parental 4T1-P, 4T1-BT and 
4T1-Luc2 (c). Values are mean ± SD; * p<0.05; ** p<0.01 from MCF10a and # p < 0.05 
from all cell lines. 
Figure 4. 6877002 reduces human and mouse breast cancer cell-induced 
osteoclastogenesis. (a-b) Concentration-response effect and half maximal inhibitory 
concentrations (IC50) of 6877002 (1-100M) on in vitro viability of human MDA-MB-
231-BT (a) and mouse 4T1-Luc2 (b) breast cancer cells after 48 hours, as assessed by 
AlamarBlue assay. (c-d) In vitro breast cancer cell-induced osteoclast formation in 
cultures of RANKL (25ng/ml) stimulated RAW.267 pre-osteoclast-like cells treated with 
vehicle or 6877002 (3μM) in the presence of human MDA-MB-231-BT (c), mouse 4T1-
Luc2 (d) cells or their conditioned medium (20%, v/v) for 72 hours, as assessed by 
TRAcP assay. (e) In vitro osteoblast viability (e) and differentiation (f) in mouse MC3T3 
pre-osteoblasts treated with vehicle or 6877002 (0.3μM) in the presence and absence of 
conditioned medium (10%, v/v) from human MDA-MB-231-BT or mouse 4T1-Luc2 for 
48 hours, as assessed by AlamarBlue and Alkaline phosphatase (ALP) assays, 
respectively. Values are mean ± SD; * p<0.05; ** p<0.01, *** p<0.005 from vehicle; # p 
< 0.05, ## p<0.01, ###p<0.005 from vehicle plus breast cancer cells or their conditioned 
medium. 
Figure 5. 6877002 reduces human MDA-MB-231-induced osteolysis. (a) Graphic 
representation of mouse calvarial organ co-culture. (a) Graphic representation of ex vivo 
 4 
mouse calvarial organ system stimulated with vehicle or IL1(100ng/ml) or co-cultured 
with osteotropic human MDA-MB-231 (MDA-231-BT) cells (300 cells/well) in the 
presence and absence of vehicle or 6877002 (3μM) for 7 days. Created with 
BioRender.com under a paid subscription. (b) ex vivo bone volume (BV/TV, %) and 
osteolysis in the mouse calvarial organ co-culture systems described in panel a. (c) Levels 
of MDA-MB-231 - and calvaria-derived factors in conditioned medium from the 
experiment described in panels a - b, as assessed by Proteome Profiler Human XL 
Cytokine Array Kit. Dotted line denotes expression in vehicle treated cells. Refer to text 
for abbreviations. (d) NFκB DNA binding in osteotropic human MDA-MB-231 (MDA-
231-BT) cells (left) and mouse M-CSF generated pre-osteoclasts (right) exposed to 
conditioned medium (20% v/v) from the MDA-MB-231 - mouse calvarial organ co-
culture system described in the experiment described in panels a – c. (e) In vitro 
chemotactic migration of osteotropic human MDA-MB-231 (MDA-231-BT) cells treated 
with vehicle or 6877002 (0-10M) in the presence and absence of RANKL (100ng/ml) 
for 16 hours, as assessed by wound healing assay. (f) Representative photomicrographs of 
osteotropic human MDA-MB-231 (MDA-231-BT) cells from the experiment described 
in panel e (scale bar = 500 m). (g) In vitro chemotactic invasion of osteotropic human 
MDA-MB-231 (MDA-231-BT) cells treated with vehicle or 6877002 (0-10M) in the 
presence and absence of RANKL (100ng/ml) for 48 hours, as assessed by Matrigel 
invasion assay. (h) Representative photomicrographs of osteotropic human MDA-MB-
231 (MDA-231-BT) cells from the experiment described in panel g (scale bar = 500 m). 
Values are mean ± SD; * p<0.05 and ** p<0.01 from vehicle; + p < 0.05 from vehicle 
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plus RANKL; $ p < 0.05 from vehicle plus IL1; # p < 0.05 from vehicle plus MDA-
MB-231-BT cells or their conditioned medium.  
Figure 6. 6877002 - alone and in combination with Docetaxel - reduces soft tissue 
and bone metastasis in immuno-competent mice bearing 4T1-Luc2 cells. (a) 
Concentration-response effect of Docetaxel (0-1nM) on in vitro viability of osteotropic 
mouse 4T1-Luc2 breast cancer cells treated with vehicle or constant dose of 6877002 
(10M) for 72 hours. Chou-Talalay method was used to calculate combination index (CI) 
values written below data points in italics. (b) Representative photomicrographs of mouse 
4T1-Luc2 breast cancer cells from the experiment described in panel a.  (scale bar = 60 
m). (c) Graphic representation of intracardiac injection of osteotropic 4T1-Luc2 cells in 
immuno-component BALB/c mice treated with vehicle (PBS), 6877002 (20mg/kg/daily) 
and/or Docetaxel (15mg/kg/week) for 11 days. Created with BioRender.com under a paid 
subscription. (d) Quantification of whole body luminescence in mice from the 
experiments described in panel c. (e) Representative photomicrographs of real-time 
bioluminescence imaging from the experiment described are shown in panels d-e. (f) 
Quantification of bone metastasis in mice from the experiments described in panels c-e. 
(g) Bone volume (BV/TV, cortex) in tibial metaphysis of mice from the experiment 
described in panels c - f. (h) Representative photomicrographs of microCT scan of mouse 
tibia from the experiment described in panels c and g. Values are mean ± SD; *p<0.05 
and **p < 0.01 from vehicle, # p < 0.05 compared to Docetaxel treated group, + p < 0.05 
compared to 6877002 treated group. 
Supplementary figures and legends 
 6 
Figure S1 (related to Fig. 1 and 2). Effects of 6877002 on TRAF/NFB signalling. (a) 
Western blot analysis of phosphorylated IKK, IKK and IB and actin in human pre-
osteoclasts after exposure to CD40L (100ng/ml) in the presence and absence of 6877002 
(0-10μM). (b-c) Immunoprecipitation and Western blot analysis of TRAF6/RANK 
binding (b) and western blot analysis of phosphorylated IKK, IKK and IB and actin 
(c) in in cultures of RAW.267 macrophage-like cells after exposure to RANKL 
(100ng/ml) in the presence and absence of 6877002 (0-10μM). (d) Western blot analysis 
of phosphorylated IB and total actin in mouse calvarial osteoblasts after exposure to 
IL1 (100ng/ml) in the presence and absence of 6877002 (0-10μM).  
Figure S2 (related to Fig. 3). Expression of RANKL is associated with bone 
metastasis in breast cancer patients. Retrospective analysis of patient samples (n = 65) 
showing increased expression of RANKL is associated with bone metastasis in breast 
cancer patients.  
Figure S3 (related to Fig. 3). TRAF6 is upregulated in osteotropic human MDA-231-
BT and mouse 4T-1 TNBC cells. Representative Western blot images of TRAF6 and 
actin in human MCF10a, MDA-MB-231, MDA-MB-231-BT and MDA-MB-231-IV (a) 
and mouse parental 4T1-P, 4T1-BT and 4T1-Luc2 (b).  
Figure S4. A schematic diagram of 6877002 effects on the NFB pathway. Upon 
CD40L-, RANKL- IL-1- binding to receptors CD40, RANK and IL-1R respectively, 
TRAF6 is recruited through binding to a conserved. In the case of IL-1R, MyD88 and 
IRAK1/4 are recruited directly to the receptor. TRAF6 binds to the same conserved motif 
in the IRAK proteins. Upon recruitment, TRAF6 is auto-ubiquitinated and acts as a 
scaffold for the recruitment and activation of the TAB1/2-TAK complex. In turn, IKK 
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and IKK are phosphorylated, which activates the IKK complex. The IKK complex 
phosphorylates IB, signalling for its destruction by the proteasome. NFB /p65 is free 
to translocate to the nucleus and initiate transcription of NFB -dependent genes (left). 
Upon pre-treatment of cells with the small molecule inhibitor of TRAF6, 6877002, it 
binds to TRAF6 preventing its binding to conserved regions in CD40, RANK and IRAK 
proteins, inhibiting its activation.  As such, the IKK complex is not phosphorylated and 
NFB remains bound to IB in the cytoplasm (right). Green proteins are active 
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